CN112450437A - 一种供高血压人群食用的药膳 - Google Patents
一种供高血压人群食用的药膳 Download PDFInfo
- Publication number
- CN112450437A CN112450437A CN202011435554.6A CN202011435554A CN112450437A CN 112450437 A CN112450437 A CN 112450437A CN 202011435554 A CN202011435554 A CN 202011435554A CN 112450437 A CN112450437 A CN 112450437A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- hypertension
- medicated diet
- mint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 34
- 230000037213 diet Effects 0.000 title claims abstract description 16
- 235000005911 diet Nutrition 0.000 title claims abstract description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- 240000008672 Gynura procumbens Species 0.000 claims abstract description 14
- 235000018457 Gynura procumbens Nutrition 0.000 claims abstract description 14
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 14
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 14
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 14
- 241000237502 Ostreidae Species 0.000 claims abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 235000020636 oyster Nutrition 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims abstract description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 12
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 12
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 12
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- 240000008042 Zea mays Species 0.000 claims abstract description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 12
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 12
- 239000011575 calcium Substances 0.000 claims abstract description 12
- 235000005822 corn Nutrition 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 12
- 239000011777 magnesium Substances 0.000 claims abstract description 12
- 239000011708 vitamin B3 Substances 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 3
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 3
- 244000046146 Pueraria lobata Species 0.000 claims description 11
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 230000001631 hypertensive effect Effects 0.000 claims description 7
- 230000036772 blood pressure Effects 0.000 abstract description 12
- 210000004185 liver Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000013403 hyperactivity Diseases 0.000 abstract description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 18
- 241000208340 Araliaceae Species 0.000 description 11
- 241000229143 Hippophae Species 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LRRJSCKXFJTRLC-GYFKHDNESA-N (2s,3as,7as)-1-[(2r)-2-[[(2s)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid;4-chloro-n-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1.C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 LRRJSCKXFJTRLC-GYFKHDNESA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NZPSYYOURGWZCM-UHFFFAOYSA-N 2-butyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one;6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C2=NNN=N2)C(CCCC)=NC21CCCC2 NZPSYYOURGWZCM-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 241000185686 Apocynum venetum Species 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 208000009693 Gingival Hyperplasia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种供高血压人群食用的药膳,涉及药膳领域,解决了现有几种高血压治疗方案存在的问题。本发明按重量份数计包括:人参1000~3000份、沙棘1000~3000份、玉米须1000~3000份、牡蛎肽1000~3000份、黄精1000~3000份、枸杞1000~3000份、平卧菊三七1000~3000份、贡菊1000~3000份、葛根1000~3000份、陈皮1000~2000份、薄荷1000~2000份、钙1000~2000份、镁300~500份、维生素C 100~500份、维生素E 100~300份、维生素B3100~300份。本发明能清热平肝、滋阴、祛瘀、缓解肝阳上亢;保护血管内皮细胞,维持血压稳定;预防并减少因高血压所引发的其他病变。
Description
技术领域
本发明涉及一种药膳,具体涉及一种供高血压人群食用的药膳。
背景技术
根据高血压调查的最新数据显示,我国高血压患病率已高达23.2%,治疗率为40.7%,控制率仅为15.3%。据预测,到2025年全球将有10.5亿高血压患者。
近年来,由于经济的快速发展和生活方式的改变,脑卒中、心脏意外等心脑血管疾病所导致的死亡率占全球人口死亡原因的30%,其中62%的脑卒中病例和49%的心肌梗死病例都是由于高血压所引起的,高血压是全球重要的死因之一。
从中医的观点分析,高血压在中医学无明确的病名,与中医“眩晕”、“头痛”关系密切,病变脏腑与肝、脾、肾等相关,主要病理因素为风、火、痰;本虚标实,其特点是以阴虚为本,阳亢为标,瘀血贯穿始终。常用的降压中成药有牛黄降压丸、罗布麻茶、脑力清、复方七芍降压片等。
然而目前高血压中医相关的理论体系没有统一标准,这严重影响了高血压中医临床规范治疗的效果。
至于西医治疗,目前治疗高血压的药物有很多,主要分为以下几种:
①钙拮抗剂(CCB):维拉帕米、非洛地平、氨氯地平、尼莫地平、硝苯地平等;
②血管紧张素转化酶抑制剂(ACEI):西拉普利、贝那普利、卡托普利、依那普利、福辛普利等;
③血管紧张素受体拮抗剂(ARB):氯沙坦、厄贝沙坦、缬沙坦、替米沙坦等;
④利尿剂:氢氯噻嗪、呋塞米、速尿、螺内酯、利尿酸、阿米洛利、氨苯喋啶、吲达帕胺等;
⑤β受体阻滞剂:比索洛尔、美托洛尔、阿替洛尔、普萘洛尔等;
⑥复方降压制剂:复方降压片、厄贝沙坦氢氯噻嗪片、复方卡托普利片、培哚普利吲达帕胺片、缬沙坦氢氯噻嗪片等。
而西药治疗高血压会出现一定的不良反应,如钙拮抗剂硝苯地平、氨氯地平适用于老年高血压单纯收缩期高血压患者,常见的不良反应有心跳加快、面部潮红、脚踝部水肿、牙龈增生等。另一方面,高血压患者服药治疗是长期性的,病程较长,远期疗效并不理想。
发明内容
为了解决中西药在治疗高血压疾病中存在的诸多问题,本发明提供了一种供高血压人群食用的药膳。
本发明为解决技术问题所采用的技术方案如下:
本发明的一种供高血压人群食用的药膳,按照重量份数计包括以下组份:
人参1000~3000份、沙棘1000~3000份、玉米须1000~3000份、牡蛎肽1000~3000份、黄精1000~3000份、枸杞1000~3000份、平卧菊三七1000~3000份、贡菊1000~3000份、葛根1000~3000份、陈皮1000~2000份、薄荷1000~2000份、钙1000~2000份、镁300~500份、维生素C 100~500份、维生素E 100~300份、维生素B3 100~300份。
作为优选的实施方式,本发明的一种供高血压人群食用的药膳,按照重量份数计包括以下组份:
人参1000份、沙棘1500份、玉米须1500份、牡蛎肽1500份、黄精1500份、构杞1500份、平卧菊三七1500份、贡菊1500份、葛根1500份、陈皮1200份、薄荷1200份、钙1200份、镁450份、维生素C 450份、维生素E 250份、维生素B3 250份。
本发明的有益效果是:
本发明是由人参、沙棘、黄精、枸杞、葛根、陈皮、薄荷、贡菊等食药物质组成,诸品合用,有清热平肝、滋阴、祛瘀、缓解肝阳上亢的作用;以牡蛎肽、平卧菊三七等组成精准营养强化部分,能够保护血管内皮细胞,维持血压稳定。
经过十几年来的临床验证证明,本发明的一种供高血压人群食用的药膳可以缓解头晕、头痛、胸闷不适等症状,维持血压稳定,预防并减少因高血压所引发的其他综合病变。
另外,本发明所使用的食药物质和营养强化物质安全、无毒副作用。
具体实施方式
本发明的一种供高血压人群食用的药膳,按照重量份数计包括以下组份:
人参1000~3000份、沙棘1000~3000份、玉米须1000~3000份、牡蛎肽1000~3000份、黄精1000~3000份、枸杞1000~3000份、平卧菊三七1000~3000份、贡菊1000~3000份、葛根1000~3000份、陈皮1000~2000份、薄荷1000~2000份、钙1000~2000份、镁300~500份、维生素C 100~500份、维生素E 100~300份、维生素B3 100~300份。
本发明中各组份的作用及功效如下:
本发明由人参、沙棘、黄精、枸杞、葛根、陈皮、薄荷、贡菊等食药物质组成,诸品合用,有清热平肝、滋阴、祛瘀、缓解肝阳上亢的作用。
本发明以牡蛎肽、平卧菊三七等组成精准营养强化部分,能够保护血管内皮细胞,维持血压稳定。
本发明的一种供高血压人群食用的药膳的制备方法具体包括以下步骤:
①按照本发明的组份及用量称取原料备用;
②将全部原料依次投入混料机内,混合均匀,以没有结块、结固为准,密封备用;
③将混匀后的复合粉投入真空干燥机内进行干燥;
④取样检测重金属、微生物;
⑤检测不合格的混料,按原因进行重新处理;合格的混料进行分装;
⑥分装后的产品进入外包装室进行外包装;
⑦现场进行质量检验,合格后入库。
本发明的一种供高血压人群食用的药膳的食用方法:
取本品1袋,温水冲泡,搅拌均匀,待温度适宜后即可食用。每次1袋,每日2次。
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
本实施例的具体组份及用量如下:
人参1000份、沙棘1500份、玉米须1500份、牡蛎肽1500份、黄精1500份、枸杞1500份、平卧菊三七1500份、贡菊1500份、葛根1500份、陈皮1200份、薄荷1200份、钙1200份、镁450份、维生素C 450份、维生素E 250份、维生素B3 250份。
本实施例的制备过程如下:
①按照本发明的组份及用量称取原料备用;
②将全部原料依次投入混料机内,混合均匀,以没有结块、结固为准,密封备用;
③将混匀后的复合粉投入真空干燥机内进行干燥;
④取样检测重金属、微生物;
⑤检测不合格的混料,按原因进行重新处理;合格的混料进行分装;
⑥分装后的产品进入外包装室进行外包装;
⑦现场进行质量检验,合格后入库。
实施例2
本实施例的具体组份及用量如下:
人参900份、沙棘1600份、玉米须1600份、牡蛎肽1400份、黄精1300份、枸杞1550份、平卧菊三七1500份、贡菊1700份、葛根1500份、陈皮1150份、薄荷1200份、钙1200份、镁450份、维生素C 450份、维生素E 250份、维生素B3 250份。
本实施例的制备过程与实施例1相同。
实施例3
本实施例的具体组份及用量如下:
人参1100份、沙棘1400份、玉米须1700份、牡蛎肽1550份、黄精1500份、构杞1550份、平卧菊三七1500份、贡菊1500份、葛根1550份、陈皮1050份、薄荷1200份、钙1000份、镁450份、维生素C 450份、维生素E 250份、维生素B3 250份。
本实施例的制备过程与实施例1相同。
实施例4
本实施例的具体组份及用量如下:
人参1000份、沙棘1550份、玉米须1400份、牡蛎肽1400份、黄精1500份、枸杞1550份、平卧菊三七1500份、贡菊1600份、葛根1500份、陈皮1350份、薄荷1250份、钙1100份、镁400份、维生素C 400份、维生素E 250份、维生素B3 250份。
本实施例的制备过程与实施例1相同。
实施例5
本实施例的具体组份及用量如下:
人参1000份、沙棘1400份、玉米须1400份、牡蛎肽1600份、黄精1500份、枸杞1600份、平卧菊三七1550份、贡菊1550份、葛根1400份、陈皮1250份、薄荷1100份、钙1250份、镁450份、维生素C 450份、维生素E 250份、维生素B3 250份。
本实施例的制备过程与实施例1相同。
实施例6
本实施例的具体组份及用量如下:
人参1200份、沙棘1400份、玉米须1600份、牡蛎肽1400份、黄精1400份、枸杞1500份、平卧菊三七1500份、贡菊1550份、葛根1500份、陈皮1300份、薄荷1200份、钙1200份、镁450份、维生素C 400份、维生素E 200份、维生素B3 200份。
本实施例的制备过程与实施例1相同。
临床试验
案例1
患者姓名:周某某
年龄:50岁
性别:男
职业:公司职员
医院诊断:高血压伴糖尿病、心悸、胸闷
有高血压家族史以及长达12年的高血压病史,平时高压135~155mm/Hg,低压93~104mm/Hg。于2019年4月29日开始服用本发明,坚持服用两周后,血压有明显的改善,并接近正常水平。服用本发明至2019年9月份时,日常测量血压,高压120~128mm/Hg,低压80~85mm/Hg,心悸、胸闷的症状也有所缓解。
案例2
患者姓名:陈某某
年龄:56岁
性别:男
职业:公司职员
医院诊断:高血压1级(轻度)
有两年高血压病史,平时高压140~158mm/Hg,低压93~96mm/Hg。于2020年5月份开始服用本发明,连续服用两周后,血压逐渐接近正常水平。坚持服用本发明至11月份时,日常测量血压,高压113~119mm/Hg,低压78~85mm/Hg,血压较稳定。
案例3
患者姓名:葛某某
年龄:53岁
性别:女
职业:无
医院诊断:高血压1级(轻度)伴高胆固醇血症
有一年的高血压病史,平时血压波动较大,高压132~150mm/Hg,低压83~97mm/Hg,有轻微胸闷。于2020年6月份开始服用本发明,连续服用一周后,血压逐渐接近正常水平,服用至6月底,血压逐渐稳定,高压110~119mm/Hg,低压73~80mm/Hg,胸闷有所缓解。
本发明公开了一种供高血压人群食用的药膳,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的产品已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的产品进行改动或适当变更与组合,来实现和应用本发明技术。
Claims (2)
1.一种供高血压人群食用的药膳,其特征在于,按照重量份数计包括以下组份:
人参1000~3000份、沙棘1000~3000份、玉米须1000~3000份、牡蛎肽1000~3000份、黄精1000~3000份、枸杞1000~3000份、平卧菊三七1000~3000份、贡菊1000~3000份、葛根1000~3000份、陈皮1000~2000份、薄荷1000~2000份、钙1000~2000份、镁300~500份、维生素C 100~500份、维生素E 100~300份、维生素B3100~300份。
2.根据权利要求1所述的一种供高血压人群食用的药膳,其特征在于,按照重量份数计包括以下组份:
人参1000份、沙棘1500份、玉米须1500份、牡蛎肽1500份、黄精1500份、枸杞1500份、平卧菊三七1500份、贡菊1500份、葛根1500份、陈皮1200份、薄荷1200份、钙1200份、镁450份、维生素C 450份、维生素E 250份、维生素B3250份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011435554.6A CN112450437A (zh) | 2020-12-11 | 2020-12-11 | 一种供高血压人群食用的药膳 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011435554.6A CN112450437A (zh) | 2020-12-11 | 2020-12-11 | 一种供高血压人群食用的药膳 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112450437A true CN112450437A (zh) | 2021-03-09 |
Family
ID=74801209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011435554.6A Pending CN112450437A (zh) | 2020-12-11 | 2020-12-11 | 一种供高血压人群食用的药膳 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112450437A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109316553A (zh) * | 2018-12-20 | 2019-02-12 | 成都四海生物科技有限公司 | 一种金钱葛精茶及其制备方法 |
CN109718272A (zh) * | 2019-02-25 | 2019-05-07 | 韩合旭 | 防治高血压的药食同源制剂 |
CN109892599A (zh) * | 2019-04-15 | 2019-06-18 | 吉林省九圣源生物科技有限公司 | 一种供冠心病人群食用的药膳 |
US20200000768A1 (en) * | 2018-07-01 | 2020-01-02 | Anthony Stampalia | Therapeutic Compositions and Uses Thereof |
CN111588833A (zh) * | 2020-07-09 | 2020-08-28 | 北京大元藏宝堂健康管理有限公司 | 一种调节高血压的产品 |
-
2020
- 2020-12-11 CN CN202011435554.6A patent/CN112450437A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200000768A1 (en) * | 2018-07-01 | 2020-01-02 | Anthony Stampalia | Therapeutic Compositions and Uses Thereof |
CN109316553A (zh) * | 2018-12-20 | 2019-02-12 | 成都四海生物科技有限公司 | 一种金钱葛精茶及其制备方法 |
CN109718272A (zh) * | 2019-02-25 | 2019-05-07 | 韩合旭 | 防治高血压的药食同源制剂 |
CN109892599A (zh) * | 2019-04-15 | 2019-06-18 | 吉林省九圣源生物科技有限公司 | 一种供冠心病人群食用的药膳 |
CN111588833A (zh) * | 2020-07-09 | 2020-08-28 | 北京大元藏宝堂健康管理有限公司 | 一种调节高血压的产品 |
Non-Patent Citations (1)
Title |
---|
梁纪文 等, 河南科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110074243A (zh) | 一种具有解酒和保护肝脏功能的压片糖果 | |
CN101278939B (zh) | 治疗心脑血管疾病的药物组合物及其制备方法 | |
CN108524493A (zh) | 二氢杨梅素组合物在抗酒精性肝氧化损伤中的应用 | |
CN101417132B (zh) | 一种含有卡维地洛和血管紧张素ⅱ受体拮抗剂的药物组合物在制备用于治疗肾病的药物中的用途 | |
CN112450437A (zh) | 一种供高血压人群食用的药膳 | |
CN101416966B (zh) | 一种治疗高血压的药物组合物 | |
CN103055201B (zh) | 一种用于治疗冠心病的中药组合物及其制备方法 | |
CN102125124A (zh) | 防治高血压的中药保健茶 | |
CN104721800B (zh) | 一种治疗冠心病的阿司匹林组合物及制备方法 | |
CN100336530C (zh) | 一种治疗高血压症的贴剂的制备方法 | |
CN104432057B (zh) | 一种具有调节内分泌功能的保健食品及其制备方法 | |
CN113424895A (zh) | 一种具有辅助降尿酸功能的压片糖果配方 | |
CN103341081A (zh) | 一种治疗高血压并蛋白尿的中药组合物 | |
CN105797141A (zh) | 一种辅助降血压的组合物及其制备方法和应用 | |
CN1861114B (zh) | 芪参益气滴丸在制备防治高原缺氧药物中的应用 | |
CN107854664A (zh) | 一种补气活血化淤降压酒及其制备方法 | |
CN101601813B (zh) | 一种治疗高血压肾损害的药物及其制备方法 | |
CN103861081A (zh) | 一种培哚普利氨氯地平片剂及其生产工艺 | |
CN107913315A (zh) | 一种治疗难治性高血压的中药组合物及其制备方法 | |
CN101347494A (zh) | 一种防治妇女更年期综合症的保健品 | |
CN110339272B (zh) | 一种治疗冠心病pci术后合并消化性溃疡的中药组合物及其制备方法 | |
CN110742898A (zh) | 一种降低血压保健方剂 | |
CN104027331A (zh) | 薏苡素降低血压的新用途 | |
CN102743361A (zh) | 厄贝沙坦氢氯噻嗪胶囊 | |
CN117256708A (zh) | 一种黄精枸杞茶、其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210309 |
|
WD01 | Invention patent application deemed withdrawn after publication |